The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Clinical experience using incubated autologous macrophages as a treatment for complete spinal cord injury: Phase I study results
Abstract
Object. A Phase I, open-label nonrandomized study was conducted to assess the safety and tolerability of incubated autologous macrophages administered to patients with acute complete spinal cord injury (SCI). Methods. This therapy was first tested in rat models of spinal cord transection and contusion, in which it was shown to promote motor recovery. The procedure developed for clinical use consists of isolating monocytes from patient blood and incubating them ex vivo with autologous dermis. The resulting incubated autologous macrophages were injected into the patient's spinal cord immediately caudal to the lesion within 14 days of injury. Patients underwent preoperative and follow-up neurological assessment (American Spinal Injury Association [ASIA] standards), electrophysiological monitoring (motor evoked and/or somatosensory evoked potentials), magnetic resonance imaging, and safety monitoring. Before macrophage administration, complete neurological functional loss (ASIA Grade A) was confirmed in all patients. Of the eight patients in the study, three recovered clinically significant neurological motor and sensory function (ASIA Grade C status). During the study period, some adverse events were encountered, the most serious of which involved two cases of pulmonary embolism and one case of osteomyelitis that were treated and resolved without further complication. These and other adverse events appear to be similar to those encountered in other spinal cord—injured patients and are not considered a consequence of the experimental therapy. Conclusions. It is concluded that incubated autologous macrophage cell therapy is well tolerated in patients with acute SCI. Further clinical evaluation is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Features of skin-coincubated macrophages that promote recovery from spinal cord injury
Bomstein, Y., Marder, J. B., Vitner, K., Smirnov, I., Lisaey, G., Butovsky, O., Fulga, V., & Yoles, E. (2003) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(03)00260-1 · Cited by 155
Self-citation
Cited by
Stem cell-based therapy for human diseases
Hoang, D. M., Pham, P. T., Bach, T. Q., Ngo, A. T. L., Nguyen, Q. T., Phan, T. T. K., Nguyen, G. H., Le, P. T. T., Hoang, V. T., Forsyth, N. R., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01134-4 · Cited by 1,074
Therapeutic interventions after spinal cord injury
Thuret, S., Moon, L. D. F., & Gage, F. H. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1955 · Cited by 1,012
Donnelly, D. J., & Popovich, P. G. (2008) · Experimental Neurology · doi:10.1016/j.expneurol.2007.06.009 · Cited by 995
From basics to clinical: A comprehensive review on spinal cord injury
Silva, N. A., Sousa, N., Reis, R. L., & Salgado, A. J. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.11.002 · Cited by 814
Spinal Cord Injury Scarring and Inflammation: Therapies Targeting Glial and Inflammatory Responses
Orr, M. B., & Gensel, J. C. (2018) · Neurotherapeutics · doi:10.1007/s13311-018-0631-6 · Cited by 583
Metadata
- Authors
- Knoller, N., Auerbach, G., Fulga, V., Zelig, G., Attias, J., Bakimer, R., Marder, J. B., Yoles, E., Belkin, M., Schwartz, M., & Hadani, M.
- Venue
- Journal of Neurosurgery: Spine
- Published
- 2005-09
- Volume
- 3
- Issue
- 3
- Pages
- 173-181
- ISSN
- 1547-5646 (ISSN-L)
- 1547-5654
- OpenAlex
- W2120528281
- Cited by
- 244
- References
- 1
- FWCI
- 9.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical experience using incubated autologous macrophages as a treatment for complete spinal cord injury: Phase I study results. https://app.cochat.ai/papers/10.3171/spi.2005.3.3.0173
- The paper
- Knoller, N., Auerbach, G., Fulga, V., Zelig, G., Attias, J., Bakimer, R., Marder, J. B., Yoles, E., Belkin, M., Schwartz, M., & Hadani, M. (2005). Clinical experience using incubated autologous macrophages as a treatment for complete spinal cord injury: Phase I study results. Journal of Neurosurgery: Spine. https://doi.org/10.3171/spi.2005.3.3.0173
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.